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Abstract
Background: Exposure to domestic violence and abuse (DVA) results in a reduction of women’s use of regular
contraceptives. This evidence suggests that women exposed to DVA are more likely to have unprotected sexual
intercourse and therefore may use more emergency contraception (EC) than those women who are not exposed to
DVA. We aimed to test this hypothesis through evaluating the evidence for an association between exposure to
DVA and use of EC.
Methods: We systematically searched eight electronic databases from inception until December 2017, checked
references and citations, and contacted corresponding authors. Primary studies that evaluated the association between
exposure to DVA and use of EC were included. Two reviewers were involved in screening, data extraction, quality
assessment and analysis. We evaluated the quality of included studies with the adapted Newcastle-Ottawa Scale. We
used tables and descriptive text to summarise and synthesise the data. Odds ratios (ORs) and 95% confidence intervals
(CIs) for each estimate of the association between DVA and use of EC were plotted on a forest plot.
Results: Our search retrieved 1216 records of which six studies with 15,297 women were included. Five studies were
observational; one study included intervention on the outcome (advance supply of EC). All studies were at high risk of
bias. Four studies provided evidence of an association between DVA and EC use – ORs from 1.51 (95% CI 1.13, 2.02) to
6.50 (95% CI 4.15, 10.17). Two studies found no evidence of a such association – ORs 0.46 (95% CI 0.11, 1.96) and 0.76
(95% CI 0.29, 1.98). The latter differed by how the authors recruited participants, measured EC use and adjusted for
confounders.
Conclusions: This systematic review provides some evidence of increased use of EC among women exposed to DVA.
Request for EC can indicate possible exposure to DVA. Therefore, each consultation for EC could be an appropriate
context for clinical enquiry about DVA and signposting/referral to specialist DVA services.
Protocol registration: PROSPERO CRD42017058221.
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Background
Domestic violence and abuse (DVA) against women is a
worldwide human rights, public health and clinical prob-
lem [1]. The UK government defines DVA as “any inci-
dent or pattern of incidents of controlling, coercive,
threatening behaviour, violence or abuse between those
aged 16 or over who are, or have been, intimate partners
or family members regardless of gender or sexuality.
The abuse can encompass, but is not limited to: psycho-
logical, physical, sexual, financial, emotional” [2]. The
World Health Organisation (WHO) estimates that ap-
proximately a third of ever-partnered women have expe-
rienced lifetime physical and/or sexual violence by an
intimate partner or sexual violence by a non-partner [3].
Health care providers are often women’s first point of
professional contact because most women attend health
services at some point, especially sexual and reproduct-
ive health services. The WHO and NICE guidelines rec-
ommend a case-finding (synonym clinical enquiry)
approach to identifying patients with experience of
DVA: healthcare providers asking those women who
present with clinical associations of DVA about safety in
their relationship and at home, and signposting or refer-
ring those who disclosed to specialist DVA services [4–6].
Therefore, professional awareness of clinical associations
of DVA is a crucial first step towards health-care response
to DVA.
DVA results in significant morbidity and disability
among women, with the biggest impact on their mental
and reproductive health [1] including an increased risk
of unintended pregnancy and abortion [7, 8]. One of the
proposed mechanisms linking DVA and unintended
pregnancy is reproductive coercion (RC), when males
control the contraceptive use and pregnancy outcomes
of their female partners [9, 10]. Recent systematic re-
views found that exposure to DVA resulted in a reduc-
tion in condom and oral contraceptive use [11, 12]. This
finding suggests that women exposed to DVA are more
likely to have unprotected sexual intercourse, and there-
fore may need more emergency contraception (EC), than
those women who are not exposed to DVA. EC with oral
(hormonal contraceptive pills levonorgestrel, or ulipristal
acetate) or intrauterine (copper intrauterine device)
method is an evidence-based intervention for preventing
unintended pregnancy [13, 14]. However, the recent re-
views [11, 12] included only one study that had EC use
as an outcome [15]. The objective of this systematic re-
view was to evaluate the evidence for an association be-
tween exposure to DVA and use of EC.
Methods
We followed the Centre for Reviews and Dissemination
[16] and Cochrane guidance for undertaking [17] and
reporting [18] systematic reviews in health care [see
PRISMA checklist in Additional file 1]. The protocol
was registered on PROSPERO (CRD42017058221).
Search strategy
MEDLINE, EMBASE and PsycINFO on OVID; CINAHL
on EBSCOhost, The Cochrane Library and Web of Sci-
ence were searched from inception to December 2017.
We used terms for DVA and combined these with terms
for EC using the Boolean operator ‘AND’. In addition,
we searched for grey literature on Google (first 6 pages),
Opengrey.eu, Clinical trial registers, websites of NHS
Choices, Department of Health, relevant medical and
pharmacy associations, and charities in the field of re-
productive health and DVA. No language or publication
restrictions were applied [Additional file 2]. Identified
references were downloaded into Endnote X7 software
and deduplicated. To find additional studies, one re-
viewer examined reference lists of the included papers,
checked their citations through the Web of Science and
contacted all corresponding authors.
Study selection
Primary studies of any design that evaluated the associ-
ation between exposure to DVA (any measure) and use of
EC were eligible for inclusion. Systematic reviews that met
this criterion were included if searches were conducted
within the past year. Studies that exclusively enrolled
pregnant women were excluded. We also excluded studies
that only considered RC without measuring DVA because
the two phenomena can occur independently [10].
Endnote references were imported into an MS Access
database developed for this study. Two reviewers inde-
pendently screened titles and abstracts and full-text papers
against the inclusion criteria. Any discrepancies between
reviewers were resolved though discussion and consensus.
All papers excluded at the full-text screening stage were
documented along with the reasons for exclusion.
Data extraction
We developed data extraction forms in MS Word and
piloted and refined these on the first three papers. To
minimise bias and errors, one reviewer extracted the
data and a second reviewer checked the extraction in de-
tail. Disagreements were resolved through discussion or
referral to a third reviewer. We extracted information on
study characteristics (author, publication year, country,
design, setting), population (age, race/ethnicity, relation-
ship status), measures of DVA and EC, cofounders, and
data on the association between DVA and EC. Where
both adjusted and crude estimates were reported, we ex-
tracted adjusted estimates. Where studies only reported
frequencies, we calculated crude odds ratios.
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Quality assessment
We adapted the Newcastle-Ottawa Scale (NOS) [19] to
assess the quality of included studies. We distinguished
between applicability and risk of bias. To assess applic-
ability, we evaluated whether the exposed group was
representative of a general population of women of re-
productive age [20] and of a country population of
women at risk of exposure to DVA [3]. Risk of bias was
assessed for the following domains:
I. Selection of the non-exposed group. Selection of ex-
posed and non-exposed groups from the same
population indicated low risk of bias.
II. Ascertainment of exposure. Measurement of DVA
through diaries or regular interviews using validated
questionnaire indicated low risk of bias.
III. Comparability of groups. Adjustment for core
cofounders (age, socioeconomic status, race/
ethnicity) and use of other reversible contraceptive
methods indicated low risk of bias [11, 12].
IV. Assessment of outcome. Measurement of EC use
through diaries or regular interviews and
ascertainment of the temporal relationship between
the exposure and outcome indicated low risk of bias.
Although NOS allocates ‘stars’ for adequate methods
we chose not to adopt this approach due to evidence
suggesting that numerical quality ratings are not helpful
in differentiating between studies of high and low risk of
bias [21]. We replaced the ‘star’ system with signalling
questions, factual questions that flag the potential for
bias, for each domain leading to an overall domain risk
of bias rating.
Analysis
Due to differences in how DVA and EC use were defined
and measured in included studies, it was not possible to
conduct a meta-analysis. We used tables and descriptive
text to summarise the data and discuss differences in re-
sults between studies. We plotted ORs and 95% confi-
dence intervals for each estimate of the association
between DVA and EC use on a forest plot, stratified by
study. Where studies reported adjusted ORs, these were
included in the plot in preference to crude ORs. We
used Stata 10 to produce the forest plot.
Results
Our search retrieved 1216 records of which six studies
(eight reports) were included (Fig. 1) [15, 22–27]. One
study was reported in three publications [24, 27, 28]. Ex-
cluded studies are listed in Additional file 3 with reasons
for exclusion.
Study characteristics
Studies were conducted in the USA [15, 22, 25], Estonia
[24, 27], Nicaragua [23] and India [26] between 2012
and 2015 and involved 15,297 women. Figure 2 summa-
rises characteristics of the included studies. An
Fig. 1. Flow of studies through the review
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additional table file describes study characteristics in de-
tail [see Additional file 4]. All studies were cross sec-
tional observations, except for Rocca et al. [26] which
included intervention on the outcome – women were
recruited, offered advance supply of EC pills and, those
who accepted the supply, were followed up for 1 year.
This study sample was also highly selective – most
women who declined the advance supply opted out be-
cause of their husbands’ disapproval of EC. Across stud-
ies, samples were drawn from general [23, 24, 26] and
clinical populations [15, 22, 25]. Data were collected
through self-administered questionnaires [22, 24, 25],
face-to-face interviews [23, 26], and examination of
medical records [15]. Most of the women were at the
younger end of the reproductive age range [20], although
the study from Estonia included older women [24].
The prevalence of DVA ranged from 4% [24] to 54%
[23], although the type and timeframe of the exposure var-
ied considerably. The exposure was measured with
self-developed questions [15, 24, 26] and standardised val-
idated questionnaires [22, 23, 25]. The studies measured
different types of DVA – from physical only [26], through
physical/ sexual [22, 24], to physical/ sexual/ emotional
[15, 25]. One study measured RC alongside physical/sex-
ual DVA [22]. The timeframe of exposure ranged from
within the past 3 months [22] to lifetime [23].
Four studies measured use of oral EC [23, 25, 26, 28],
while two studies did not explicitly state which method
of EC was assessed [15, 22]. Use of EC was assessed on a
continuum from “following the most recent sexual inter-
course” [24] to “lifetime” [23]. Only one study measured
the frequency of EC use [22].
Quality assessment
Only the Nicaraguan study was applicable to both the
general population of women of reproductive age and
country DVA population [23] (Table 1). Other studies
were considered at high concern for applicability as in-
cluded women were at the younger end of the reproduct-
ive age range [22, 26] and of lower socioeconomic status
compared to a country DVA population [15, 25]. All six
studies were at high risk of bias on at least one domain.
Association of DVA with EC use
Four studies provided evidence of an association between
DVA and EC use (Fig. 3). The largest Nicaraguan study by
Fig. 2 Studies characteristics
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Salazar et al. (n = 8234) [23] found strong evidence of an
association for all types of DVA with no evidence of a dif-
ference between them – ORs ranged from 1.51 (95% CI
1.13, 2.02) to 1.82 (95% CI 1.30, 2.55). The American
study by Fantasia et al. [15] explored associations between
DVA exposure over four time-periods and EC use in the
past year. This study found the strongest association for
EC use and DVA in the past year (OR 6.50, 95% CI 4.15,
10.17). Exposure in the past year and extending beyond
this to the past five or more years or historical DVA
showed weaker associations (OR 2.00, 95% CI 1.33, 3.00
to 2.20, 95% CI 0.61, 7.99). Kazmerski et al. [22] cate-
gorised exposure as DVA alone, or DVA + RC, and mea-
sured EC use as “once”, or “more than once”, over the
past 3 months. For women who had experienced DVA +
RC, there was no association between exposure and use of
EC once (OR 0.90, 95% CI 0.50, 1.62), but a strong associ-
ation between exposure and use of EC more than once
(OR 2.40, 95% CI 1.41, 4.09) [22]. Gee et al. [25] evaluated
lifetime exposure to DVA and EC use within the past year
and found weak evidence of an association (OR 1.75, 95%
CI 0.91, 3.36).
Two studies found no evidence of an association be-
tween DVA and use of EC [24, 26]. The Estonian study
by Laanpere et al. [24] was the only one that did not re-
port adjusted ORs. This study also measured EC use at
one time point, while other studies assessed outcome
over a specific time period. The Indian study by Rocca
et al. [26] was based on a highly self-selected sample and
had an intervention on the outcome – advance supply of
EC.
Discussion
Main findings
This systematic review of six studies with 15,297 women
provides some evidence of increased use of EC among
women exposed to DVA. The evidence is applicable to
younger women in high- and middle-income countries.
Four studies suggested that women who have experi-
enced DVA are more likely to use EC compared to other
women, while two studies did not find such a link. Null
findings in the latter can be explained by the differences
in how the authors recruited participants, measured EC
use, and dealt with confounders. The included studies
had high concerns regarding applicability and were at
high risk of bias for ascertainment of exposure, compar-
ability of exposed and unexposed groups, and assess-
ment of outcome.
Our findings are in line with a recent meta-analysis
which showed a causal relationship between exposure to
DVA and reduction in use of regular contraception
methods [11]. Our findings support previous research
linking DVA and unprotected intercourse through RC
[10, 29]. The Kazmerski’s study [22] suggests that
women exposed to DVA and RC might use EC instead
of regular contraception.
The two studies that did not find an association be-
tween DVA and EC use had some important differences
Table 1 Applicability and risk of bias assessed with the adapted Newcastle Ottawa Scale
Study first author, year Fantasia
2012
Gee
2013
Laanpere
2013
Rocca
2013
Salazar
2014
Kazmerski
2015
Applicability of study sample
1. Representative of the general population of women of reproductive age
Is the study sample representative of the female population of reproductive age?
No No No No Yes No
2. Representative of the general DVA population
Is the study sample truly representative of the coutry DVA population?
No Yes No No Yes No
Risk of bias
I. Selection of the non-exposed group
Is the non-exposed group drawn from the same population
as the exposed group?
Low Low Low Low Low Low
II. Ascertainment of exposure
Was the ascertainment of exposure prospective?
Was the exposure measured with a valid methos of assessment?
High High High High High High
III. Comparability of groups
Did study control for age, socio-economic status, race/ethnicity,
use of other reversible contraception methods?
High Low High High High High
IV. Assessment of outcome
Was the ascertainment of outcome prospective?
Was the outcome ascertained with a valid methos of assessment?
Was the temporality of the outcome vs exposure assessed?
High High High High High High
Overall risk of bias for study High High High High High High
Quality appraisal tool is the Newcastle-Ottawa Scale [19] adapted for this study. DVA domestic violence and abuse. Overall risk of bias for study is a reflection of
the least favourable assessment for a single domain - e.g. if one domain is high risk whole study is high risk. Signalling questions that flag the potential for bias
are shown in italic: Answer 'Yes' to signaling question indicates high risk of bias, answer 'No' indicates low risk of bias
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from those studies that did report an association. The
Estonian study [24] reported unadjusted ORs and only
looked at EC use following the most recent intercourse.
Such measure of the outcome at a single time point is
likely to underestimate actual EC use over a 12-month
timeframe of exposure. Although authors reported
socio-demographic and sexual health characteristics of
the sample, they did not adjust for these when assessing
the association between DVA and EC use. This could re-
sult in biased estimate of the association. The Indian
study [26] based on a highly selective sample provided
all women with an advance supply of EC which made it
easier to use it whether or not they were exposed to
DVA. The improved access to EC across the sample
could have impact on the actual association.
In addition, the association between DVA and EC use
can be influenced by wider contextual factors such as
awareness about EC among women and health-care pro-
viders, cultural and religious beliefs and attitudes, and
acceptability and accessibility of EC and other methods
of birth control [30, 31]. Accessibility depends on which
services provide EC (e.g., pharmacy, general practice,
hospital) and whether women must pay. Where EC is
expensive or inaccessible, women who have restricted
autonomy and access to resources may be disadvan-
taged. In consequence, there may be no difference in EC
use between abused and non-abused women, because
the greater need of the former is attenuated by poorer
access. The four studies supporting the association be-
tween DVA and use of EC were conducted in USA and
Nicaragua where abortion services are less acceptable
and accessible than hormonal EC [32, 33]. In contrast,
in Estonia abortion services are widely available and ac-
ceptable to women with unintended pregnancy [28]. In
India, EC awareness and acceptability among women
and health care providers are rather low [34–36].
Limitations of the evidence base
We only found a small number of eligible primary studies,
all of which had methodological limitations. Five out of six
studies were cross-sectional surveys most of which did
not control for the core DVA and EC covariates and medi-
ator. Unmeasured confounders (e.g., socio-cultural norms
regarding EC, accessibility of EC) could result in biased ef-
fect estimates. Although response rates for completion of
questionnaires recording DVA and EC were generally
high, there was a potential for differences between re-
sponders and non-responders which was not investigated
by any of the studies. All studies relied on retrospective re-
call of the exposure and outcome which is likely to have
led to either an underestimate or overestimate of the asso-
ciation between DVA and EC use. Self-report of DVA in
all studies is likely to have resulted in under-reporting due
to the stigma and social desirability [37]. The gold
Fig. 3 Forest plots: Odds ratios and 95% confidence intervals for use of emergency contraception among those exposed compared to those not
exposed to domestic violence and abuse
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standard for researching DVA is a face-to-face interview,
conducted by a specially trained researcher in a private
setting [38]. However, only two studies used this method
to evaluate the exposure [23, 26]. Only two studies mea-
sured multiple types of DVA – physical, sexual, emotional
[15, 23]; the rest used narrow definitions as only physical
[26] or physical/ sexual [22, 25, 28]. Not measuring emo-
tional, psychological and financial types of DVA can result
in general under-reporting of the exposure. None of the
studies specifically asked about the use of the copper
intrauterine device as a form of EC. While four studies
specifically asked about EC pills, two did not clarify which
EC method(s) they assessed [15, 22]. It is therefore pos-
sible that women in the latter studies reported use of both
methods. If this is the case, EC use may have been
under-reported in the four studies which asked women
about EC pills.
Strengths and limitations of the review
This is the first review to synthesise quantitative evi-
dence of the association between exposure to DVA and
use of EC. The review protocol was pre-registered in the
publicly available database to ensure transparency. We
used a comprehensive, sensitive search strategy across
multiple databases including sources of grey literature,
followed by hand searches of references and citations
and contact with experts. This comprehensive approach
means that it is unlikely that we have missed relevant
studies. However, a formal assessment of the potential
for publication bias was not possible due to the small
number of included studies. We took steps throughout
the review process to reduce the potential for bias and
errors. Two reviewers independently screened titles and
abstracts and assessed full text studies for inclusion.
Data extraction and risk of bias assessment were per-
formed by one reviewer and checked in detail by a sec-
ond, and a validated tool was used to assess study
quality. The small number of studies, and the different
ways in which DVA and EC use were measured, meant
that it was not appropriate to conduct a meta-analysis.
Conclusion
This systematic review of six studies with 15,297 women
provides some evidence of increased use of EC among youn-
ger women exposed to DVA in high- and middle-income
countries. Our findings are relevant to healthcare practi-
tioners, policy makers and commissioners involved in
provision of EC. Women exposed to DVA need easy access
to EC, which can be provided via different services free of
charge. Request for EC can indicate possible exposure to
DVA. Therefore, each consultation for EC could be an ap-
propriate context for clinical enquiry about DVA and sign-
posting/referral to specialist DVA services. Healthcare
settings where EC is provided are suitable for the safe
display of information about DVA, its impact on health, and
local DVA services. DVA interventions for health-care prac-
titioners should be targeted at core providers of EC and in-
clude new evidence on an association between exposure to
DVA and use of EC.
Future studies on women’s health should use a longi-
tudinal design and embed validated measures of DVA
and RC alongside other factors associated with women’s
health, and EC use alongside other reproductive health
outcomes.
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